生殖系多能性转录因子基因多态性预测西妥昔单抗治疗转移性结直肠癌的疗效
本研究探索多能性转录因子(PTF)基因的生殖系单核苷酸多态性(SNP)与转移性结直肠癌(mCRC)患者西妥昔单抗或贝伐珠单抗疗效的关系。利用三个独立临床试验队列的基因组与临床数据,检测10个SNP与临床结局的关联。结果显示,在西妥昔单抗队列中,NANOG和NANOGP8基因的4个SNP与无进展生存期显著相关,而贝伐珠单抗队列中未观察到显著关联。
要点
- NANOG rs11055767、rs10744044及NANOGP8 rs2168958、rs2279066与西妥昔单抗疗效相关。
- NANOGP8 rs2168958和rs2279066在多因素分析中仍显著。
- 贝伐珠单抗队列中未发现显著关联。
核心结论
- PTF基因的生殖系多态性可能作为mCRC中西妥昔单抗的预测标志物。
研究设计与样本
- 研究纳入三个独立临床试验队列:西妥昔单抗队列(FIRE-3中FOLFIRI/西妥昔单抗组,n=129)、贝伐珠单抗队列1(FIRE-3中FOLFIRI/贝伐珠单抗组,n=107)和贝伐珠单抗队列2(TRIBE中FOLFIRI/贝伐珠单抗组,n=215)。
主要发现
- 西妥昔单抗队列中,单因素分析显示NANOG rs11055767(任何A等位基因 vs C/C,HR=0.62,95%CI 0.42-0.94,p=0.02)、NANOG rs10744044(任何A等位基因 vs G/G,HR=0.59,95%CI 0.39-0.90,p=0.01)、NANOGP8 rs2168958(任何C等位基因 vs A/A,HR=2.12,95%CI 1.36-3.29,p<0.001)和NANOGP8 rs2279066(任何C等位基因 vs T/T,HR=1.80,95%CI 1.06-1.68,p=0.03)与无进展生存期显著相关。
- 多因素分析证实NANOGP8 rs2168958和rs2279066的显著关联。
- 在两个贝伐珠单抗队列中,单因素分析均未观察到显著关联。
临床怎么用
- 对于mCRC患者,检测PTF基因的生殖系多态性可能有助于筛选西妥昔单抗治疗的潜在获益人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer stem cells (CSCs) are primarily maintained by a network of pluripotency transcription factors (PTFs). Given a close relationship of CSC regulation with epidermal growth factor receptor and vascular endothelial growth factor signalling, we investigated whether single-nucleotide polymorphisms (SNPs) in PTF genes are related to the efficacy of cetuximab and/or bevacizumab in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Genomic and clinical data from three independent clinical trial cohorts were tested: cetuximab cohort (FOLFIRI/cetuximab arm in FIRE-3, n = 129), bevacizumab cohort 1 (FOLFIRI/bevacizumab arm in FIRE-3, n = 107) and bevacizumab cohort 2 (FOLFIRI/bevacizumab arm in TRIBE, n = 215). Genomic DNA extracted from blood samples was genotyped, and ten SNPs were tested for association with clinical outcomes. RESULTS: In the cetuximab cohort, four SNPs were significantly associated with progression-free survival in univariate analysis: NANOG rs11055767 (any A allele vs C/C, hazard ratio [HR] = 0.62, 95% confidence interval [CI] = 0.42-0.94, p = 0.02), NANOG rs10744044 (any A allele vs G/G, HR = 0.59, 95% CI = 0.39-0.90, p = 0.01), NANOGP8 rs2168958 (any C allele vs A/A, HR = 2.12, 95% CI = 1.36-3.29, p < 0.001) and NANOGP8 rs2279066 (any C allele vs T/T, HR = 1.80, 95% CI = 1.06-1.68, p = 0.03). Multivariate analysis confirmed the significant associations for NANOGP8 rs2168958 and NANOGP8 rs2279066. In either bevacizumab cohort, no significant associations were observed in univariate analysis. CONCLUSIONS: Germ line polymorphisms in the PTF genes could be predictive markers for cetuximab in mCRC.
引用
- Arai H, Millstein J, Loupakis F, et al. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. Eur J Cancer. 2021. PMID: 33901792. doi:10.1016/j.ejca.2021.03.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。